Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort.
Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding / Ciccullo, A; Borghi, V; Giacomelli, A; Cossu, M V; Sterrantino, G; Latini, A; Giacometti, A; De Vito, A; Gennari, W; Madeddu, G; Capetti, A; D'Ettorre, G; Mussini, C; Rusconi, S; Di Giambenedetto, S; Baldin, G. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 88:3(2021), pp. 234-237. [10.1097/QAI.0000000000002787]
Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding
Mussini, C;
2021
Abstract
Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Five_years_with_dolutegravir_plus_lamivudine_as_a_switch_strategy,JAIDS_AoP_Aug2021pdf.pdf
Open access
Tipologia:
AAM - Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione
1.24 MB
Formato
Adobe PDF
|
1.24 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
